Bioventus (BVS) vs vVARDIS (VVVV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
vVARDIS is the larger company by market cap ($770.9 million vs $676.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | VVVV |
|---|---|---|
| Share price | $9.88 | $14.55 |
| Market cap | $676.53M | $770.91M |
| 1-day change | -0.70% | -3.00% |
| YTD return | +32.80% | — |
| 1-year return | +36.46% | — |
| 5-year return | -21.02% | — |
| P/E ratio (TTM) | 12.20 | — |
| Forward P/E | 11.13 | — |
| EPS (TTM) | $0.81 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $568.09M | — |
| Revenue growth (YoY) | -0.91% | — |
| Net income (latest FY) | $22.73M | — |
| Gross margin | 68.33% | — |
| Operating margin | 9.50% | — |
| Net margin | 4.00% | — |
| 52-week high | $15.89 | $16.95 |
| 52-week low | $7.02 | $14.00 |
| Distance from 52-week high | -37.83% | -14.16% |
| Analyst consensus | none | — |
| Avg. price target upside | +68.02% | — |
| Average volume | 536.81K | 963.08K |
| Shares outstanding | 68.47M | 38.59M |
| Employees | 960 | 153 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 960 employees
About vVARDIS
VVVV stock →vVARDIS Holding AG, a dental medtech company, develops and provides non-invasive cavity treatment products in Switzerland and the United States. The company offers the Curodont platform, including Curodont Repair, a biomimetic system to arrest and reverse early caries through enamel regeneration; Curodont Protect, a remineralising tooth gel containing the biomimetic Oligo-Peptide 103 technology; and Enamel Serum, enriched with peptides and hydroxyapatite, which delivers calcium and phosphate ions to care for the enamel.
Health Care · Medical/Dental Instruments · 153 employees
BVS vs VVVV FAQ
Which is bigger, Bioventus or vVARDIS?
vVARDIS (VVVV) is larger, with a market capitalization of $770.91M compared with $676.53M for Bioventus (BVS).
Are Bioventus and vVARDIS in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.